COMMUNIQUÉS West-GlobeNewswire

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
05/04/2024
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting ULBP6 23ME-00610, [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/04/2024
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024
05/04/2024
Preclinical data shows promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors ZÜRICH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced the presentation of [...]
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
05/04/2024
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer mouse model - Late-breaking [...]
Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024
05/04/2024
Studies demonstrated novel ADCs combining two TOP1i payloads with different features have the potential to maximize ADC efficacy and improve therapeutic index AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- [...]
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
05/04/2024
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT) , a late-stage biopharmaceutical company dedicated to improving the lives of patients [...]
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023
05/04/2024
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 5 avril 2024 – GENFIT (Nasdaq et Euronext: GNFT) , société biopharmaceutique de stade clinique avancé engagée dans l’amélioration de la vie des [...]
NeuroVigil, World’s Most Valuable Neurotech, Launches iBrain™ in US
05/04/2024
CLOSED 6 BILLION DOLLAR SERIES B DEAL SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- Silicon Valley-based Neurotechnology Powerhouse, announced that it launched its non-invasive iBrain™ Personal Brain Monitor, in 4 [...]
EchoNous Announces Revolutionary AI Enhancements in Upcoming Kosmos Release for Apple iOS
05/04/2024
REDMOND, Wash., April 05, 2024 (GLOBE NEWSWIRE) -- EchoNous, a leading innovator in ultrasound technology, is thrilled to announce the upcoming Kosmos 2.2 release on Apple iOS, a monumental update enriched with powerful [...]
Availability of the 2023 Universal Registration Document, including the Annual Financial Report
05/04/2024
Press Release Paris – April 5, 2024 – EUROAPI announces the publication of its 2023 Universal Registration Document, filed with the French Autorité des marchés financiers (AMF) on April 5, 2024. The 2023 Universal [...]
Mise à disposition du Document d’Enregistrement Universel 2023, contenant le Rapport Financier Annuel
05/04/2024
Communiqué de presse Paris – Le 5 avril 2024 – EUROAPI annonce la publication de son Document d’Enregistrement Universel 2023, déposé auprès de l’Autorité des marchés financiers (AMF) le 5 avril 2024. Le Document d’ [...]
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
05/04/2024
Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial [...]
PHAXIAM Therapeutics annonce le dépôt de son Document d’Enregistrement Universel (URD) 2023
05/04/2024
Lyon (France) et Cambridge (MA, US), le 5 avril 2024 – 18h00 CEST – PHAXIAM Therapeutics (Euronext : PHXM ; FR0011471135) société biopharmaceutique qui développe des traitements innovants contre les infections [...]
Activation of PA Licensure Compact to Improve Access to Patient Care
05/04/2024
PA compact will eliminate unnecessary barriers to PA practice across state lines ALEXANDRIA, Va., April 05, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA), Federation of State Medical [...]
Theratechnologies Appoints Elina Tea to its Board of Directors
05/04/2024
MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of [...]
Theratechnologies nomme Elina Tea à son conseil d’administration
05/04/2024
MONTRÉAL, 05 avr. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur la mise au point et la commercialisation de [...]
Hapbee Received Commitments for $2.785 Million From Qualified Investors
05/04/2024
VANCOUVER, British Columbia, April 05, 2024 (GLOBE NEWSWIRE) -- Hapbee Technologies , Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) (“Hapbee” or the “Company”), the digital wellness technology company has announced on [...]
Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit
05/04/2024
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Medicovestor, Inc. has been chosen as one of 11 finalists from a competitive pool of over 150 applicants spanning more than 20 countries to showcase its innovative Antibody- [...]
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
05/04/2024
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the publication of “ [...]

Pages